The who stopped testing several drugs against coronavirus

The world health organization (who) has stopped trials of hydroxychloroquine, or a combination of the drugs lopinavir and ritonavir as drugs to combat coronavirus infection COVID-19. This was reported on the who website.

A recommendation given by the international steering Committee of the so-called tests of solidarity, which aims to develop a treatment for patients with COVID-19.

In the study, experts tested how drugs affect the mortality rate from disease caused by a virus SARS-CoV-2. Preliminary results showed that hydroxychloroquine and lopinavir/ritonavir only marginally help to reduce mortality among patients with COVID 19, or generally does not affect it, according to the organization.

Gidroksilamin, and the combination of lopinavir and ritonavir was included in the list of tested drugs in the framework of international clinical studies of Solidarity. Who together with partners initiated it in March with the aim to find effective drug for the treatment of COVID-19.

In late may, the organization had suspended trials of hydroxychloroquine because of concerns about his security. The head of the who tedros adhanom Ghebreyesus referred to a study which suggested increased mortality among patients taking the drug. In June, the who expert Anna Maria Restrepo reported that his tests will drop.

Hydroxychloroquine — antimalarial drug. In may, the President of the United States, Donald trump told me that taking it as a prevention against COVID-19. Before that, Reuters wrote that it put pressure on health authorities in the USA, so they are allowed to market a drug for malaria as drugs for the treatment of coronavirus infection.

Lopinavir and ritonavir is usually used in the treatment of human immunodeficiency virus (HIV). In late June, the leaders of Britain’s RECOVERY clinical study said that the combination of these drugs useless for treating COVID-19. To this conclusion they came, having compared data of 1.5 thousand patients receiving these medications, with data from 3.3 thousand of patients who received conventional treatment.

The combination of lopinavir and ritonavir was also included in the list of drugs recommended by the Ministry of healthcare for the treatment of coronavirus infection. On 3 July the Agency has updated recommendations for the treatment of diseases in children. The document States that this drug is no longer recommended either adults or children, as there is no evidence of its efficacy and safety.

According to who, in the course of testing antiviral drugs against encouraging results COVID-19 showed while only ramdevpir, which was originally developed as part of the testing for the treatment of hepatitis C and respiratory syncytial virus. In the organization reported that patients who took this drug, was recovering faster.